Delafloxacin (Baxdela) for skin infection

Research output: Contribution to journalArticle

Abstract

Delafloxacin (Baxdela) is a fluoroquinolone antibiotic labeled for the treatment of adults with serious acute bacterial skin and skin structure infections, including those caused by Staphylococcus aureus (methicillin-sensitive and methicillinresistant), Enterococcus faecalis, and Pseudomonas aeruginosa.1 Although delafloxacin is approved by the U.S. Food and Drug Administration for a strictly oral regimen, patients enrolled in the clinical trials that led to approval required three days of initial intravenous therapy followed by oral therapy.

Original languageEnglish (US)
Pages (from-to)246-247
Number of pages2
JournalAmerican family physician
Volume98
Issue number4
StatePublished - Aug 15 2018

Fingerprint

Skin
Infection
Methicillin
Enterococcus faecalis
Fluoroquinolones
United States Food and Drug Administration
Pseudomonas
Staphylococcus aureus
Therapeutics
Clinical Trials
Anti-Bacterial Agents
ABT 492

All Science Journal Classification (ASJC) codes

  • Family Practice

Cite this

Delafloxacin (Baxdela) for skin infection. / Eudaley, Sarah.

In: American family physician, Vol. 98, No. 4, 15.08.2018, p. 246-247.

Research output: Contribution to journalArticle

@article{ae22ee41699444709e524656830572d4,
title = "Delafloxacin (Baxdela) for skin infection",
abstract = "Delafloxacin (Baxdela) is a fluoroquinolone antibiotic labeled for the treatment of adults with serious acute bacterial skin and skin structure infections, including those caused by Staphylococcus aureus (methicillin-sensitive and methicillinresistant), Enterococcus faecalis, and Pseudomonas aeruginosa.1 Although delafloxacin is approved by the U.S. Food and Drug Administration for a strictly oral regimen, patients enrolled in the clinical trials that led to approval required three days of initial intravenous therapy followed by oral therapy.",
author = "Sarah Eudaley",
year = "2018",
month = "8",
day = "15",
language = "English (US)",
volume = "98",
pages = "246--247",
journal = "American Family Physician",
issn = "0002-838X",
publisher = "American Academy of Family Physicians",
number = "4",

}

TY - JOUR

T1 - Delafloxacin (Baxdela) for skin infection

AU - Eudaley, Sarah

PY - 2018/8/15

Y1 - 2018/8/15

N2 - Delafloxacin (Baxdela) is a fluoroquinolone antibiotic labeled for the treatment of adults with serious acute bacterial skin and skin structure infections, including those caused by Staphylococcus aureus (methicillin-sensitive and methicillinresistant), Enterococcus faecalis, and Pseudomonas aeruginosa.1 Although delafloxacin is approved by the U.S. Food and Drug Administration for a strictly oral regimen, patients enrolled in the clinical trials that led to approval required three days of initial intravenous therapy followed by oral therapy.

AB - Delafloxacin (Baxdela) is a fluoroquinolone antibiotic labeled for the treatment of adults with serious acute bacterial skin and skin structure infections, including those caused by Staphylococcus aureus (methicillin-sensitive and methicillinresistant), Enterococcus faecalis, and Pseudomonas aeruginosa.1 Although delafloxacin is approved by the U.S. Food and Drug Administration for a strictly oral regimen, patients enrolled in the clinical trials that led to approval required three days of initial intravenous therapy followed by oral therapy.

UR - http://www.scopus.com/inward/record.url?scp=85053391546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053391546&partnerID=8YFLogxK

M3 - Article

VL - 98

SP - 246

EP - 247

JO - American Family Physician

JF - American Family Physician

SN - 0002-838X

IS - 4

ER -